Zydus, Novartis Settle Patent Suit on Generic Version of Jadenu

Zydus Cadila sued Novartis in December, seeking a U.S. judicial declaration that its copycat of the 180-milligram tablet doesn’t infringe a patent for the drug Jadenu, which is used to treat chronic iron overload.

• No details were provided in the agreement, approved Tuesday in federal court in Newark, New Jersey
• Novartis and Cipla last week settled a lawsuit in which Cipla was seeking a declaration that its copycat doesn’t infringe the same patent
• Jadenu had U.S. sales of $450 million in 2019, 14% less than in 2018, Novartis said Jan. 29 in its annual report
  • Novartis attributed the decline ...